Effect of atorvastatin in patients with chronic heart failure - insights from randomized clinical trials.
Effect of atorvastatin in patients with chronic heart failure - insights from randomized clinical trials.
复制标题
DOI：
10.5114/aoms.2010.19293
复制
发表时间：
2010-12
期刊：
影响因子：
--
通讯作者：
Wei F
中科院分区：
文献类型：
--
作者：
Xu M;Yuan G;Wei F
最近的大型临床试验显示，瑞舒伐他汀在慢性心力衰竭(CHF)人群中的疗效令人失望。仍然存在的问题是，瑞舒伐他汀的这些研究结果是否可以推广到其他他汀类药物。因此，我们基于目前所有可用的随机对照试验(RCT)进行了一项荟萃分析，以评估阿托伐他汀对CHF患者的临床疗效。对截至2010年1月的电子数据库进行正式搜索，扫描已发表的文献。如果在CHF患者中比较阿托伐他汀和安慰剂治疗，并报告临床结果，RCT有资格纳入。涉及540名患者的7项试验符合预先规定的标准。与安慰剂相比，使用阿托伐他汀治疗的心力衰竭患者的主要终点--全因死亡率显著降低(优势比[OR0.39，P=0.002)，心血管死亡率(OR0.28，P=0.002)和心源性猝死(OR0.24，P=0.002)的结果相似。与安慰剂相比，阿托伐他汀治疗CHF恶化的住院时间也显著减少(OR0.3，P<；0.001)。这一荟萃分析表明，阿托伐他汀治疗在降低CHF患者全因死亡率和恶化CHF住院的风险方面是有效的。需要进一步的大型随机试验来证实阿托伐他汀或其他他汀类药物相对于安慰剂或瑞舒伐他汀治疗CHF的益处。
Recent large clinical trials have yielded disappointing results of rosuvastatin in the chronic heart failure (CHF) population. The question that remains is whether these results of rosuvastatin studies could be extended to other statins. Therefore, we performed a meta-analysis based on all currently available randomized controlled trials (RCTs) to evaluate the clinical efficacy of atorvastatin in CHF patients. The published literature was scanned by formal searches of electronic databases up to January 2010. RCTs were eligible for inclusion if they compared atorvastatin versus placebo treatment in patients with CHF and reported the clinical outcomes. Pre-specified criteria were met by 7 trials involving 540 patients. The primary endpoint, all-cause mortality, was significantly reduced with atorvastatin therapy compared with placebo in CHF patients (odds ratio [OR] 0.39, P = 0.002), with similar results in cardiovascular mortality (OR 0.28, P = 0.002) and sudden cardiac death (OR 0.24, P = 0.01). There was also a significant decrease in hospitalization for worsening CHF with atorvastatin therapy compared with placebo (OR 0.30, P < 0.001). This meta-analysis suggests the effectiveness of atorvastatin treatment in reducing the risks of all-cause mortality and worsening CHF hospitalization in patients with CHF. Further large, well-conducted randomized trials are needed to confirm the benefits of atorvastatin or other statins for CHF relative to placebo or rosuvastatin.
登录
查看更多内容
影响因子：
120.7
作者：
de Lemos, JA;Blazing, MA;Braunwald, E
通讯作者：
Braunwald, E
DOI：
10.1016/0197-2456(86)90046-2
发表时间：
1986-09-01
期刊：
CONTROLLED CLINICAL TRIALS
影响因子：
--
作者：
DERSIMONIAN, R;LAIRD, N
通讯作者：
LAIRD, N
影响因子：
2.8
作者：
Mozaffarian, D;Minami, E;Levy, WC
通讯作者：
Levy, WC
影响因子：
37.8
作者：
Khush, Kiran K.;Waters, David D.;Wenger, Nanette K.
通讯作者：
Wenger, Nanette K.
影响因子：
105.7
作者：
Higgins, JPT;Thompson, SG;Altman, DG
通讯作者：
Altman, DG